All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Khaled et al. reviewed the diagnosis and treatment of Acute Myeloid Leukemia (AML) to provide insights into the emerging novel biomarkers, new molecular approaches and therapeutic agents that are anticipated to be useful for the implementation of personalized medicine in AML. This review has implications for the management of patients with the most unmet needs; older patients and patients with high-risk disease. Their findings were published in Oncology (Williston Park) in April 2016.1
Hypomethylating agents (HMAs), including 5-azacytidine or decitabine, may be an effective approach in older patients. The effectiveness of these agents was observed in two large randomized trials. Also of note are the results of a landmark 10-day regimen of decitabine, 20mg/m2, in previously untreated older AML patients which demonstrated a 47% complete remission (CR) rate and a 64% overall response (OR) rate.
Nucleophosmin (NPM) is a nucleolar phosphoprotein that normally shuttles between the nucleus and the cytoplasm to maintain cellular processes. Frameshift mutations at the C-terminus of this protein are relatively common in cytogenic-normal (CN-AML) patients (occurring in 45% to 60% of this subset). In older CN-AML patients treated with intensive induction chemotherapy, NPM1 mutations predict for excellent disease response and better survival.
SGN-CD33A, a humanized CD33 antibody conjugated to a pyrrolobenzodiazepine (PBD), has shown promising results in AML patients. Early results from a phase I clinical trials have recently been presented. In one trial of SGN-CD33A monotherapy in patients who had CD33-positive AML in relapse or who had declined intensive induction chemotherapy, a dose of 40μg/kg led to a 60% OR rate in treatment-naïve patients.
In summary, in order to improve outcomes in AML patients, the challenge is how to match molecular and clinical information with emerging compounds in order to select the best treatment for individual patients. The success of personalized approaches in AML is likely to depend on the ability to readily attain molecular information and improve patient access to new drugs.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox